Michael E. Hurwitz
Yale Cancer Center(US)Yale University(US)University of New Haven(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Renal cell carcinoma treatment, Immunotherapy and Immune Responses, Bladder and Urothelial Cancer Treatments
Most-Cited Works
- → Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology(2019)1,555 cited
- → Prostate Cancer, Version 1.2016(2016)651 cited
- → Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)(2020)232 cited
- → A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors(2019)229 cited
- → Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy(2020)166 cited
- → CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma(2024)127 cited